Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04069273 · ClinicalTrials.gov registry record · Phase 2

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

A Phase 2 study of Gastric Cancer and Adenocarcinoma, sponsored by Harry H Yoon.

Recruiting
Registry status
Phase 2
Development phase
58
Enrollment target
2
Study locations

NCT04069273 is a Phase 2 study of Gastric Cancer and Adenocarcinoma that is actively recruiting participants, run by Harry H Yoon. The registered enrollment target is 58 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04069273, a Phase 2 study of Gastric Cancer and Adenocarcinoma, is actively recruiting participants, sponsored by Harry H Yoon.

RECRUITING
Registry status
Phase 2
Development phase
58 participants
Enrollment target
2
Study locations

Study Summary

Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.

Conditions Studied

Gastric Cancer Adenocarcinoma GastroEsophageal Cancer

Interventions

  • DRUG Paclitaxel
  • DRUG Ramucirumab
  • DRUG Pembrolizumab Monotherapy

Study Locations (2)

Minnesota

  • Mayo Clinic- Minnesota - Rochester

Wisconsin

  • Froedtert and The Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2020-12-01
Est. Completion 2026-12-10
Phase Phase 2

Sponsor

Harry H Yoon

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04069273

The ClinicalTrials.gov registry entry for NCT04069273 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Harry H Yoon, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.

NCT04069273 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT04069273 about?

NCT04069273 is a clinical study titled "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma". Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with pacl...

What is the current status of trial NCT04069273?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2020-12-01. Estimated completion is 2026-12-10.

What conditions does trial NCT04069273 study?

This clinical trial studies the following conditions: Gastric Cancer, Adenocarcinoma, GastroEsophageal Cancer.

What interventions are being tested in trial NCT04069273?

The interventions under investigation include: Paclitaxel (DRUG), Ramucirumab (DRUG), Pembrolizumab Monotherapy (DRUG).

Who is sponsoring clinical trial NCT04069273?

This trial is sponsored by Harry H Yoon, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04069273 being conducted?

This trial has 2 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Adenocarcinoma

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.